Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 13,860,000 | 14,358,000 | 14,836,000 | 13,620,000 | 13,558,000 |
| Cost of Goods | 3,611,000 | 3,539,000 | 3,322,000 | 3,227,000 | 3,324,000 |
| Gross Profit | 10,249,000 | 10,819,000 | 11,514,000 | 10,393,000 | 10,234,000 |
| Operating Expenses | 6,633,000 | 6,318,000 | 6,650,000 | 5,730,000 | 6,704,000 |
| Operating Income | 3,616,000 | 4,501,000 | 4,864,000 | 4,663,000 | 3,530,000 |
| Interest Expense | 304,000 | 281,000 | 289,000 | 270,000 | 275,000 |
| Other Income | -94,000 | -24,000 | -44,000 | 14,000 | 30,000 |
| Pre-tax Income | 3,218,000 | 4,196,000 | 4,531,000 | 4,407,000 | 3,285,000 |
| Income Tax | 814,000 | 266,000 | 507,000 | 798,000 | 465,000 |
| Net Income Continuous | 2,404,000 | 3,930,000 | 4,024,000 | 3,609,000 | 2,820,000 |
| Minority Interests | -5,000 | 2,000 | -17,000 | 3,000 | 2,000 |
| Net Income | $2,409,000 | $3,928,000 | $4,041,000 | $3,606,000 | $2,818,000 |
| EPS Basic Total Ops | 1.27 | 2.04 | 2.07 | 1.83 | 1.43 |
| EPS Basic Continuous Ops | 1.26 | 2.04 | 2.07 | 1.83 | 1.42 |
| EPS Diluted Total Ops | 1.25 | 2.02 | 2.06 | 1.82 | 1.40 |
| EPS Diluted Continuous Ops | 1.24 | 2.03 | 2.05 | 1.82 | 1.40 |
| EPS Diluted Before Non-Recurring Items | 2.03 | 2.25 | 2.42 | 2.28 | 1.98 |
| EBITDA(a) | $5,152,000 | $4,501,000 | $4,864,000 | $5,858,000 | $5,190,000 |